A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation
Treated with Anlotinib.
10.3779/j.issn.1009-3419.2018.05.13
- Author:
Yudong SU
1
;
Zhaoting MENG
1
;
Xiaoyan XU
1
;
XinYue WANG
1
;
Ran ZUO
1
;
Yunxia HOU
1
;
Kai LI
1
;
Peng CHEN
1
Author Information
1. Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin 300060, China.
- Publication Type:Case Reports
- Keywords:
Advanced lung cancer;
Anlotinib;
Lung neoplasms
- MeSH:
Adenocarcinoma;
drug therapy;
enzymology;
genetics;
pathology;
Adenocarcinoma of Lung;
Aged;
Antineoplastic Agents;
therapeutic use;
Humans;
Indoles;
therapeutic use;
Lung Neoplasms;
drug therapy;
enzymology;
genetics;
pathology;
Male;
Mutation;
Proto-Oncogene Proteins p21(ras);
genetics;
metabolism;
Quinolines;
therapeutic use
- From:
Chinese Journal of Lung Cancer
2018;21(5):428-430
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, the number of advanced non-small cell lung cancer (NSCLC) patients has gradually increased, and the treatment methods have also been significantly increased. However, there are no standard treatment plans at home and abroad for third-line and above patients who are refractory to targeted therapy epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) or chemotherapy. The clinical treatment effect is also not satisfactory. Anlotinib is a novel TKI targeting the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR) and c-Kit. ALTER0303 trail, phase III study has demonstrated that Anlotinib significantly prolonged overall survival (OS) and progression-free survival (PFS) in advanced NSCLC patients as 3rd line treatment.Here we report a case of advanced lung adenocarcinoma harboring KRAS mutation treated with Anlotinib.
.
